The experimental evidence that Adhesion G Protein-Coupled Receptors (aGPCRs) functionally couple to heterotrimeric G proteins has been emerging in incremental steps, but attributing biological significance to their G protein signalling function still presents a major challenge. Here, utilising activated truncated forms of the receptors, we show that ADGRE2/EMR2 and ADGRE5/CD97 are G protein-coupled in a variety of recombinant systems. In a yeast-based assay, where heterologous GPCRs are coupled to chimeric G proteins, EMR2 showed broad G protein-coupling, whereas CD97 coupled more specifically to G α12 , G α13 , G α14 and G αz chimeras. Both receptors induced pertussis-toxin (PTX) insensitive inhibition of cyclic AMP (cAMP) levels in mammalian cells, suggesting coupling to G αz. EMR2 was shown to signal via G α16 , and via a G α16 /G αz chimera, to stimulate IP 1 accumulation. Finally, using an NFAT reporter assay, we identified a polyclonal antibody that activates EMR2 G protein signalling in vitro. Our results highlight the potential for the development of soluble agonists to understand further the biological effects and therapeutic opportunities for ADGRE receptor-mediated G protein signalling. The Adhesion G Protein-Coupled Receptors (aGPCRs) constitute an evolutionarily ancient membrane protein family with emerging roles in many important biological processes (for reviews see 1-5). The receptors each contain a 7-transmembrane (7-TM) domain with phylogeny suggesting ancestry to the 'Family B' (Secretin receptor family; also known as Class B) G Protein-Coupled Receptors (GPCRs). However, aGPCRs are distinguished by their large amino-terminal regions that typically contain multiple modular motifs such as EGF (Epidermal Growth Factor-like), cadherin and immunoglobulin domains as well as novel lineage-specific structures. While these are generally thought to mediate inter-cellular 'adhesion' interactions, various examples suggest separable roles for the extracellular domain (ECD) and 7-TM regions 6,7. This complexity, apart from the sheer size of some of the receptors, underlies some of the challenges of studying aGPCRs. As the known interacting partners of aGPCRs are usually tethered to other cells, their identification and characterisation have been difficult. Of those identified, including CD55 for CD97 8 , transglutaminase II (TGII) for GPR56 9 and chondroitin sulphate B (dermatan sulphate) for EMR2 10 , few had measurable effects on G protein signalling in vitro and it is not clear whether these partners can be considered 'ligands' , as understood for the better characterised Family A (Rhodopsin-like), Family B (Secretin receptor family) or Family C (Metabotropic glutamate family) GPCRs, that modulate G protein signalling pathways in response to the binding of soluble activators. Indeed, only recently has evidence become compelling of aGPCR association with G protein alpha subunits (reviewed in Langenhan et al. 11), changes in second messenger levels 11 , and GTP turnover in membranes from cells expressing a...